Vaccine Development Global Program

Developing new, affordable vaccines for the people who need them most

Vaccines are one of the most effective, affordable, and beneficial tools in public health. Because market forces alone are not always strong enough to drive the development of vaccines most urgently needed in lower-income countries, PATH’s Vaccine Development Global Program is stepping in to fill the gap. Find out more »


New award to support development of novel vaccine against bacterial diarrhea

Photo credit: PATH/Richard Walker

PATH recently received a Translation Fund award from the Wellcome Trust to support the clinical development of DB Fusion, a novel, serotype-independent vaccine candidate to prevent Shigella dysentery. The new award provides funding of more than US$4 million over 30 months. We also posted a blog highlighting some of the exciting aspects of this new funding. Read the announcement »

Highlights

blog: Learn about how India is working to meet the Millennium Development Goals »

website: Visit the new website for PATH’s Better Immunization Data Initiative »

survey: Help PATH identify the global health innovations that have the most promise to accelerate progress »

blog: Start planning your Global Handwashing Day celebration for Oct. 15 »

website: Check out PATH’s new online portal for global health advocacy »


Sign up for our e-newsletter

Our e-newsletter, Vaccines for the Future, provides quarterly updates on our efforts to develop innovative, safe, effective, and affordable vaccines. It includes updates on our progress, partnerships, and specific activities. Sign up now »


Visit the Vaccine Resource Library

PATH’s Vaccine Resource Library (VRL) seeks to gather the world’s best immunization resources in a single, easy-to-use website. The VRL offers high-quality, scientifically accurate documents and links on specific diseases and topics in immunization. Learn more »


Banner photos, clockwise from left: PATH/Gabe Bienczycki; PATH/Chutima Suraratdecha; PATH.

Comments are closed.